Galt Gets FDA Priority Review for Opioid-Free Pain Management Drug

Pharmaceutical industry innovator Galt Pharmaceuticals aims to give physicians and patients an opioid-free alternative for the management of pain. The company submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte and has been provided a Priority Review goal date for approval by August 14, 2019.

“Healthcare providers simply need more choices as they look for non-controlled opioid free alternatives for pain management and our goal is to offer one more proven alternative before prescribing an opioid or controlled medication,” said Galt CEO and co-founder Barry Patel, Pharm.D.

Orphengesic Forte is an oral non-controlled combination muscle relaxant pain reliever. The oral tablets contain 50 mg of Orphenadrine Citrate, 770 mg of Aspirin and 60 mg of Caffeine. It is indicated for the relief of mild to moderate pain of acute musculoskeletal disorders, paired with rest and physical therapy.

“We strongly believe that we can reverse the opioid crisis in advancing better practices for pain management by continuing to bring non-opioid alternatives to market,” said Galt Chairman Wade Smith, Pharm.D. “Our portfolio will continue to expand with various other non-opioid pain medications in the coming years.”

https://www.biospace.com/article/releases/galt-pharmaceuticals-receives-fda-priority-review-for-non-controlled-pain-management-drug-orphengesic-forte-an-opioid-free-alternative-for-patients/